Tilray Brands announced a strategic partnership that will expand its medical‑cannabis distribution in Germany, effective April 1, 2026. The alliance brings together Tilray Pharma, Tilray Medical, CC Pharma, 14U Pharma, and the “gesund leben” cooperation operated by Alliance Healthcare Deutschland.
The partnership grants Tilray preferred access to more than 20% of German pharmacies through CC Pharma and extends reach to about 3,600 member pharmacies via the “gesund leben” network. Alliance Healthcare supplies over 10,000 pharmacies daily and operates 27 logistics centers, providing a robust supply‑chain backbone for Tilray’s pharmaceutical‑grade products.
Germany is the largest medical‑cannabis market in Europe, and by leveraging CC Pharma’s network and Alliance Healthcare’s logistics, Tilray positions itself to capture a larger share of prescription sales and strengthen its international footprint.
Management highlighted the strategic value of the deal: Rajnish Ohri said the partnership “strengthens Tilray’s German operations, expands pharmacy access, and creates an even more powerful platform for long‑term growth.” Irwin D. Simon noted the growth opportunities stemming from Germany’s updated cannabis policy.
Tilray already secured one of the first cultivation licenses under the Medical Cannabis Act (MedCanG) and operates a pharmaceutical distribution platform. The new alliance builds on that foundation and is expected to accelerate market penetration.
The expanded network should improve product availability, streamline supply chain operations, and potentially boost revenue in a high‑growth region, reinforcing Tilray’s strategy to grow its international medical‑cannabis footprint.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.